Literature DB >> 25212463

Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.

Chandana Buddhala1, Meghan C Campbell2, Joel S Perlmutter3, Paul T Kotzbauer4.   

Abstract

Accumulation of misfolded α-synuclein (α-syn) protein in Lewy bodies and neurites is the cardinal pathologic feature of Parkinson disease (PD), but abnormal deposition of other proteins may also play a role. Cerebrospinal fluid (CSF) levels of proteins known to accumulate in PD may provide insight into disease-associated changes in protein metabolism and their relationship to disease progression. We measured CSF α-syn, amyloid β₁₋₄₂ (Aβ₁₋₄₂), and tau from 77 nondemented PD and 30 control participants. CSF α-syn and Aβ₁₋₄₂ were significantly lower in PD compared with controls. In contrast with increased CSF tau in Alzheimer disease, CSF tau did not significantly differ between PD and controls. CSF protein levels did not significantly correlate with ratings of motor function or performance on neuropsychological testing. As expected, CSF Aβ₁₋₄₂ inversely correlated with [(11)C]-Pittsburgh compound B (PiB) mean cortical binding potential, with PiB(+) PD participants having lower CSF Aβ₁₋₄₂ compared with PiB(-) PD participants. Furthermore, CSF α-syn positively correlated with Aβ₁₋₄₂ in PD participants but not in controls, suggesting a pathophysiologic connection between the metabolisms of these proteins in PD.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aβ(1–42); Cerebrospinal fluid; Imaging; Nondemented; Parkinson’s disease; PiB; Tau; α-Synuclein

Mesh:

Substances:

Year:  2014        PMID: 25212463      PMCID: PMC4268043          DOI: 10.1016/j.neurobiolaging.2014.07.043

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  68 in total

1.  Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease.

Authors:  H I Hurtig; J Q Trojanowski; J Galvin; D Ewbank; M L Schmidt; V M Lee; C M Clark; G Glosser; M B Stern; S M Gollomp; S E Arnold
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

2.  Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom.

Authors:  Peter Hobson; Jolyon Meara
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

3.  Imaging amyloid deposition in Lewy body diseases.

Authors:  S N Gomperts; D M Rentz; E Moran; J A Becker; J J Locascio; W E Klunk; C A Mathis; D R Elmaleh; T Shoup; A J Fischman; B T Hyman; J H Growdon; K A Johnson
Journal:  Neurology       Date:  2008-09-16       Impact factor: 9.910

4.  Phosphorylated α-synuclein in Parkinson's disease.

Authors:  Yu Wang; Min Shi; Kathryn A Chung; Cyrus P Zabetian; James B Leverenz; Daniela Berg; Karin Srulijes; John Q Trojanowski; Virginia M-Y Lee; Andrew D Siderowf; Howard Hurtig; Irene Litvan; Mya C Schiess; Elaine R Peskind; Masami Masuda; Masato Hasegawa; Xiangmin Lin; Catherine Pan; Douglas Galasko; David S Goldstein; Poul Henning Jensen; Hui Yang; Kevin C Cain; Jing Zhang
Journal:  Sci Transl Med       Date:  2012-02-15       Impact factor: 17.956

5.  Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.

Authors:  L Narhi; S J Wood; S Steavenson; Y Jiang; G M Wu; D Anafi; S A Kaufman; F Martin; K Sitney; P Denis; J C Louis; J Wypych; A L Biere; M Citron
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

7.  Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.

Authors:  Olga Pletnikova; Neva West; Michael K Lee; Gay L Rudow; Richard L Skolasky; Ted M Dawson; Laura Marsh; Juan C Troncoso
Journal:  Neurobiol Aging       Date:  2004-12-28       Impact factor: 4.673

8.  Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

Authors:  Sara Hall; Annika Öhrfelt; Radu Constantinescu; Ulf Andreasson; Yulia Surova; Frederick Bostrom; Christer Nilsson; Widner Håkan; Hilde Decraemer; Katarina Någga; Lennart Minthon; Elisabet Londos; Eugeen Vanmechelen; Björn Holmberg; Henrik Zetterberg; Kaj Blennow; Oskar Hansson
Journal:  Arch Neurol       Date:  2012-11

9.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

Authors:  Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

10.  Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease.

Authors:  Lucilla Parnetti; Lucia Farotti; Paolo Eusebi; Davide Chiasserini; Claudia De Carlo; David Giannandrea; Nicola Salvadori; Viviana Lisetti; Nicola Tambasco; Aroldo Rossi; Nour K Majbour; Omar El-Agnaf; Paolo Calabresi
Journal:  Front Aging Neurosci       Date:  2014-03-31       Impact factor: 5.750

View more
  25 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

2.  Group comparison of spatiotemporal dynamics of intrinsic networks in Parkinson's disease.

Authors:  Tara M Madhyastha; Mary K Askren; Jing Zhang; James B Leverenz; Thomas J Montine; Thomas J Grabowski
Journal:  Brain       Date:  2015-07-14       Impact factor: 13.501

3.  Cognitive reserve and β-amyloid pathology in Parkinson disease.

Authors:  Carolyn Lucero; Meghan C Campbell; Hubert Flores; Baijayanta Maiti; Joel S Perlmutter; Erin R Foster
Journal:  Parkinsonism Relat Disord       Date:  2015-05-27       Impact factor: 4.891

4.  CSF proteins and resting-state functional connectivity in Parkinson disease.

Authors:  Meghan C Campbell; Jonathan M Koller; Abraham Z Snyder; Chandana Buddhala; Paul T Kotzbauer; Joel S Perlmutter
Journal:  Neurology       Date:  2015-05-15       Impact factor: 9.910

5.  Sleep Deprivation Affects Tau Phosphorylation in Human Cerebrospinal Fluid.

Authors:  Nicolas R Barthélemy; Haiyan Liu; William Lu; Paul T Kotzbauer; Randall J Bateman; Brendan P Lucey
Journal:  Ann Neurol       Date:  2020-02-27       Impact factor: 10.422

6.  Emergent Functional Network Effects in Parkinson Disease.

Authors:  Caterina Gratton; Jonathan M Koller; William Shannon; Deanna J Greene; Baijayanta Maiti; Abraham Z Snyder; Steven E Petersen; Joel S Perlmutter; Meghan C Campbell
Journal:  Cereb Cortex       Date:  2019-06-01       Impact factor: 5.357

Review 7.  PET Imaging in Movement Disorders.

Authors:  Baijayanta Maiti; Joel S Perlmutter
Journal:  Semin Nucl Med       Date:  2018-08-16       Impact factor: 4.446

8.  TMEM230 in Parkinson's disease.

Authors:  Laura Ibanez; Umber Dube; John Budde; Kathleen Black; Alexandra Medvedeva; Albert A Davis; Joel S Perlmutter; Bruno A Benitez; Carlos Cruchaga
Journal:  Neurobiol Aging       Date:  2017-03-16       Impact factor: 4.673

9.  Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease.

Authors:  Corey T McMillan; David A Wolk
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-06-09       Impact factor: 10.154

Review 10.  Amyloid-β and Parkinson's disease.

Authors:  Ee Wei Lim; Dag Aarsland; Dominic Ffytche; Raquel Natalia Taddei; Daniel J van Wamelen; Yi-Min Wan; Eng King Tan; Kallol Ray Chaudhuri
Journal:  J Neurol       Date:  2018-10-30       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.